---
title: "Illumina, Inc. (ILMN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ILMN.US.md"
symbol: "ILMN.US"
name: "Illumina, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T12:57:08.133Z"
locales:
  - [en](https://longbridge.com/en/quote/ILMN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ILMN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ILMN.US.md)
---

# Illumina, Inc. (ILMN.US)

## Company Overview

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.illumina.com](https://www.illumina.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.29% |  |
| Net Profit YoY | 188.30% |  |
| P/B Ratio | 8.01 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 21436184000.00 |  |
| Revenue | 4393000000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 33.82% | A |
| Profit Margin | 19.42% | A |
| Gross Margin | 67.64% | A |
| Revenue YoY | 1.29% | C |
| Net Profit YoY | 188.30% | A |
| Total Assets YoY | 6.10% | C |
| Net Assets YoY | 13.01% | B |
| Cash Flow Margin | 132.24% | B |
| OCF YoY | 1.29% | C |
| Turnover | 0.69 | B |
| Gearing Ratio | 59.20% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Illumina, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.29%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "188.30%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.01",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "21436184000.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4393000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "33.82%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "19.42%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "67.64%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.29%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "188.30%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.10%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.01%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.29%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.69",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "59.20%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 25.13 | 10/59 | 28.21 | 22.77 | 12.19 |
| PB | 8.01 | 48/59 | 8.19 | 6.92 | 6.50 |
| PS (TTM) | 4.88 | 39/59 | 4.70 | 4.20 | 3.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 40% |
| Overweight | 3 | 15% |
| Hold | 6 | 30% |
| Underweight | 2 | 10% |
| Sell | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 141.68 |
| Highest Target | 175.00 |
| Lowest Target | 95.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ILMN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ILMN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ILMN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ILMN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**